Evidence map›Paper›PMID 34403325›Full record

ArticlePharmaceutical biology2021

Kaempferol-induced GPER upregulation attenuates atherosclerosis via the PI3K/AKT/Nrf2 pathway.

Zhuo Feng, Changyuan Wang, Yue, Jin, Qiang Meng, Jingjing Wu, Huijun Sun

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 3 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Kaempferol-A Natural Drug for Rheumatoid Arthritis.Chinese journal of integrative medicine · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Multitargeted Effects ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhuo FengThe First Affiliated Hospital of Dalian Medical University, Dalian, China.
Changyuan WangDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
Yue
JinDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
Qiang MengDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
Jingjing WuDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
Huijun SunAcademy of Integrative Medicine, Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0003-4474-6966
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextThe effect of kaempferol, a regulator of oestrogen receptors, on atherosclerosis (AS) and the underlying mechanism is elusive.

objectiveTo explore the effect and mechanism of kaempferol on AS. METHODS AND MATERIALS:

results

conclusionsThe beneficial effects of kaempferol against postmenopausal AS are associated with the PI3K/AKT/Nrf2 pathways, mediated by the activation of GPER.

Indexed as

AnimalsAortaApoptosisAtherosclerosisCells, CulturedCell SurvivalDose-Response Relationship, DrugEndothelial CellsFemaleHumansKaempferolsLipoproteins, LDLMiceMice, Inbred C57BLMice, Knockout, ApoENF-E2-Related Factor 2GPER1 protein, mousekaempferolKaempferolsLipoproteins, LDLNfe2l2 protein, mouseNF-E2-Related Factor 2oxidized low density lipoproteinPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktReactive Oxygen SpeciesReceptors, EstrogenReceptors, G-Protein-CoupledapoptosisInflammationoxidized low-density lipoprotein (ox-LDL)traditional Chinese medicines (TCM)

Identifiers

PMID34403325
PMCPMC8436971
OpenAlexW3193596810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.